Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bliss GVS Pharma's Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹1,238 Mil. Therefore, Bliss GVS Pharma's EV-to-EBIT ratio for today is 7.78.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bliss GVS Pharma's Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹1,502 Mil. Therefore, Bliss GVS Pharma's EV-to-EBITDA ratio for today is 6.41.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Bliss GVS Pharma's Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹7,702 Mil. Therefore, Bliss GVS Pharma's EV-to-Revenue ratio for today is 1.25.
Bliss GVS Pharma Enterprise Value Historical Data
The historical data trend for Bliss GVS Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bliss GVS Pharma's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's Enterprise Value falls into.
Bliss GVS Pharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bliss GVS Pharma's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bliss GVS Pharma (NSE:BLISSGVS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bliss GVS Pharma's current Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,238 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bliss GVS Pharma's current Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,502 Mil.
Bliss GVS Pharma's current Enterprise Value is ₹9,625 Mil.
Bliss GVS Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7,702 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bliss GVS Pharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Bliss GVS Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bliss GVS Pharma (NSE:BLISSGVS) Business Description
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Geographically, it derives a majority of revenue from Outside India. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:BLISSGVS has been successfully added to your 